Recipharm acquires Abbott's Spanish biopharmaceutical manufacturing
1 Oct 2010
Swedish company Recipharm AB has acquired Abbott’s manufacturing site near Barcelona, Spain for an undisclosed sum.
The site, which will now be called Recipharm Parets SL, produces solid dose, sterile ointments, oral liquids, aerosols and topical products.
This move further enhances Recipharm’s capabilities, providing a base in the strategically important Spanish market, whilst bringing new customer relationships into the Recipharm Group. It also reinforces Recipharm’s strategic goal to become one of the world’s leading contract development and manufacturing organisations (CDMO), offering a ‘one-stop shop’ for the development and manufacturing of both small and large molecule biopharmaceuticals.
Recipharm will continue to produce all Abbott products currently manufactured at the site. Recipharm says it also intends to retain all existing employees.
Thomas Eldered, CEO of Recipharm, said: “We are extremely pleased to be entering into another transaction with Abbott and to be building on the successful integration of the Fontaine les Dijon facility which we acquired last year from former Solvay Pharmaceuticals. Both the facilities and staff are first class and we look forward to nurturing and developing current and new business in the important Spanish market”.
Recipharm AB is a contract development and manufacturing organisation headquartered near Stockholm and with about 1950 employees. The Company operates several development and manufacturing facilities in Sweden, France, the UK and Germany. It supplies over six hundred products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, and dry powder inhalers. It also has biologics development capabilities.